Accessibility Menu
 
Dbv Technologies logo

Dbv Technologies

(NASDAQ) DBVT

Current Price$19.98
Market Cap$1.11B
Since IPO (2014)-93%
5 Year-62%
1 Year+412%
1 Month-10%

Dbv Technologies Financials at a Glance

Market Cap

$1.11B

Revenue (TTM)

$0.00

Net Income (TTM)

$147.31M

EPS (TTM)

$-5.27

P/E Ratio

-3.81

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$19.98

Volume

9,820

Open

$20.96

Previous Close

$19.98

Daily Range

$19.70 - $21.45

52-Week Range

$5.75 - $26.18

DBVT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dbv Technologies

Industry

Biotechnology

Employees

125

CEO

Daniel Tassé

Headquarters

Montrouge, 92120, FR

DBVT Financials

Key Financial Metrics (TTM)

Gross Margin

-10%

Operating Margin

-200%

Net Income Margin

-195%

Return on Equity

-150%

Return on Capital

-86%

Return on Assets

-63%

Earnings Yield

-26.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.11B

Shares Outstanding

55.66M

Volume

9.82K

Short Interest

0.00%

Avg. Volume

343.90K

Financials (TTM)

Gross Profit

$17.67M

Operating Income

$153.16M

EBITDA

$135.49M

Operating Cash Flow

$121.18M

Capital Expenditure

$533.64K

Free Cash Flow

$121.18M

Cash & ST Invst.

$194.17M

Total Debt

$21.68M

Dbv Technologies Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$4.28M

-937.5%

Gross Margin

0.00%

N/A

Market Cap

$1.11B

N/A

Market Cap/Employee

$10.50M

N/A

Employees

106

N/A

Net Income

$44.80M

-94.6%

EBITDA

$41.38M

-78.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$172.48M

+599.5%

Accounts Receivable

$16.15M

+55.4%

Inventory

$0.00

N/A

Long Term Debt

$5.41M

-14.1%

Short Term Debt

$16.27M

+985.0%

Return on Assets

-62.98%

N/A

Return on Invested Capital

-85.78%

N/A

Free Cash Flow

$35.61M

-193.6%

Operating Cash Flow

$35.60M

-190.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANROAlto Neuroscience, Inc.
$20.50-1.54%
LBRXLB Pharmaceuticals Inc Common Stock
$23.84-2.81%
ANNXAnnexon, Inc.
$5.00-4.76%
LXEOLexeo Therapeutics, Inc. Common Stock
$5.46-3.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.56-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$87.42+0.06%
IBITiShares Bitcoin Trust
$37.40-0.04%

Questions About DBVT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.